MediSapiens said this week that it is developing a platform to support cancer genomics data management and analysis for Bayer Healthcare.
The Finnish bioinformatics company said that it will work with Bayer to develop a platform based on MediSapiens' existing infrastructure that will help the pharmaceutical firm's researchers "more effectively" use their oncology data in both preclinical and clinical research settings.
MediSapiens develops web applications for genomics, pharmaceutical research, and personalized medicine. The company recently released a map of human gene expression for public use through its Transcriptome viewer tool (BI 9/30/2011).
The Bayer project will allow MediSapiens to use the expertise it has gleaned from building and managing its unified gene expression database, Sami Kilpinen, MediSapiens chief scientific officer, said in a statement.